IJCM  Vol.5 No.14 , July 2014
PPPM (Predictive, Preventive and Personalized Medicine) as a New Model of the National and International Healthcare Services and Thus a Promising Strategy to Prevent a Disease: From Basics to Practice
Abstract: Nowadays the system of public health is constructed in such a manner so that its main objective is the recovery of an already sick person, while prediction and prevention receive little attention. Meanwhile the development of these aspects of medicine can lead to the ability to control morbidity among the population, to identify chronic and genetic diseases in the early stages of development, and thus to prevent their further progression. This will reduce traditionally high costs of sick people treatment and the number of disabled population, and improve the quality and duration of life. The elaboration of new fields of science that are working on the study and interpretation of data obtained during laboratory and clinical research, creation of new methods for diagnosis, prognosis and treatment, provides an opportunity now to implement a new strategy, called PPPM, and gets promising results, which should lead to further development of an existing medicine.
Cite this paper: Sadkovsky, I. , Golubnitschaja, O. , Mandrik, M. , Studneva, M. , Abe, H. , Schroeder, H. , Antonova, E. , Betsou, F. , Bodrova, T. , Payne, K. and Suchkov, S. (2014) PPPM (Predictive, Preventive and Personalized Medicine) as a New Model of the National and International Healthcare Services and Thus a Promising Strategy to Prevent a Disease: From Basics to Practice. International Journal of Clinical Medicine, 5, 855-870. doi: 10.4236/ijcm.2014.514115.

[1]   Ray, R. (2012) The Future of Medicine. American Journal of Medicine, 125, 236-239.

[2]   Gabibov, A.G., Paltsev, M.A. and Suchkov, S.V. (2011) Antibody-Associated Proteolysis in Surveillance of Autoimmune Demyelination: Clinical and Preclinical Issues. Future Neurology, 6, 303-305.

[3]   Bodrova, T.A., Kostyushev, D.S., Antonova, E.N., Slavin, S., Gnatenko, D.A., Bocharova, M.O., Legg, M., Pozzilli, P., Paltsev, M.A. and Suchkov, S.V. (2012) Introduction into PPPM as a New Paradigm of Public Health Service: An Integrative View. EPMA Journal, 3, 16.

[4]   Golubnitschaja, O. and Costigliola, V. (2010) Common Origin but Individual Outcomes: Time for New Guidelines in Personalised Healthcare. Personalized Medicine, 7, 561-568.

[5]   Nair, V.S., Maeda, L.S. and Ioannidis, J.P. (2012) Clinical Outcome Prediction by microRNAs in Human Cancer: A Systematic Review. Journal of the National Cancer Institute, 104, 528-540.

[6]   Jones, T. and Price, P. (2012) Development and Experimental Medicine Applications of PET in Oncology: A Historical Perspective. Lancet Oncology, 13, e116-e125.

[7]   Patel, N.R., McPhail, M.J., Shariff, M.I., Keun, H.C. and Taylor-Robinson, S.D. (2012) Biofluid Metabonomics Using (1)H NMR Spectroscopy: The Road to Biomarker Discovery in Gastroenterology and Hepatology. Expert Review of Gastroenterology and Hepatology, 6, 239-251.

[8]   Hood, L., Balling, R. and Auffray, C. (2012) Revolutionizing Medicine in the 21st Century through Systems Approaches. Biotechnology Journal, 7, 992-1001.

[9]   Tran, B., Dancey, J.E., Kamel-Reid, S., McPherson, J.D., Bedard, P.L., Brown, A.M., Zhang, T., Shaw, P., Onetto, N., Stein, L., Hudson, T.J., Neel, B.G. and Siu, L.L. (2012) Cancer Genomics: Technology, Discovery, and Translation. Journal of Clinical Oncology, 30, 647-660.

[10]   Scott, S.A. (2011) Personalizing Medicine with Clinical Pharmacogenetics. Genetics in Medicine, 13, 987-995.

[11]   Saubermann, A.J. and Lagasse, R.S. (2012) Prediction of Rate and Severity of Adverse Perioperative Outcomes: “Normal Accidents” Revisited. Mount Sinai Journal of Medicine, 79, 46-55.

[12]   Lemke, H.U. and Berliner, L. (2011) Patient Specific Modeling and Model Guided Therapy. EPMA Journal, 2, 181-182.

[13]   Farra, N., Manickaraj, A.K., Ellis, J. and Mital, S. (2012) Personalized Medicine in the Genomics Era: Highlights from an International Symposium on Childhood Heart Disease. Future Cardiology, 8, 157-160.

[14]   Kostyushev, D., Tsarev, I., Gnatenko, D., Paltsev, M. and Suchkov, S. (2011) Myelin-Associated Serological Targets as Applicable to Diagnostic Tools to Be Used at the Preclinical and Transient Stages of Multiple Sclerosis Progression. Open Journal of Immunology, 1, 80-86.

[15]   Jain, K.K. (2012) Role of Nanodiagnostics in Personalized Cancer Therapy. Clinics in Laboratory Medicine, 12, 15-31.

[16]   Khitrov, A.N., Shogenov, Z.S., Tretyak, E.B., Ischenko, A.I., Matsuura, E., Neuhaus, O., Paltsev, M.A. and Suchkov, S.V. (2007) Postinfectious Immunodeficiency and Autoimmunity: Pathogenic and Clinical Values and Implications. Expert Review of Clinical Immunology, 3, 323-331.

[17]   Robinton, D.A. and Daley, G.Q. (2012) The Promise of Induced Pluripotent Stem Cells in Research and Therapy. Nature, 481, 295-305.

[18]   Sheiman, I. and Shishkin, S. (2010) New Challenges and New Objectives Problems of Economic Transition. Russian Health Care, 52, 4-49.